Tag:
Valeant
Latest Headlines
Latest Headlines
Pharma dealmakers, the price is right for Sweden's Meda
Sweden's biggest drugmaker is currently trading at just 5.4 times its cash flow projected for 2013, Bloomberg points out, cheaper than 95% of its specialty pharma rivals with $1 billion-plus market values. It's a 70% discount in terms of sales and net assets, too.
Another day, another deal for Valeant's Pearson
Valeant Pharmaceuticals ( $VRX ) made the M&A news again today: This time, the Canadian drugmaker scored some assets from Atlantis Pharma, a Mexican branded-generics company, for $71 million.
ISTA's hard-to-get stance yields $500M Bausch & Lomb bid
After resisting a bidfrom Valeant, ISTA went to Bausch & Lomb for 40% more.
Valeant nabs Russia's Natur Produkt for $175M-plus
The Canadian drugmaker has made yet another acquisition. This time, it's an OTC company in a deal potentially worth $180 million.
Serbian bribery probe highlights emerging-markets danger
A Serbian bribery probe serves up a cautionary tale for drugmakers relying on emerging markets for growth. Reuters digs into the years-long corruption investigation, relating a plot that could have...
After dropping ISTA, Valeant nabs another eye-drug company
So what if Valeant Pharmaceuticals wasn't able to pull off its bid for ISTA Pharmaceuticals? It's snapping up Eyetech instead. The Canadian drugmaker ( $VRX ) agreed to pay "significantly less than two
Valeant counts itself out of ISTA's strategic options
Valeant Pharmaceuticals CEO Michael Pearson has walked away from another deal. The Canadian drugmaker withdrew its $7.50-per-share bid to acquire ISTA Pharmaceuticals, one day ahead of its official
Valeant targets $200M in post-merger cost cuts
Whether Valeant Pharmaceuticals' ( $VRX ) latest news is good or bad depends upon your point of view. If you're an investor or analyst, it's good: The company forecast estimate-beating earnings and
Which pharmas win the hedge-fund popularity contest?
You know the proverb: A man is known by the company he keeps. Well, a company can be known by the company it keeps, too. At least that's the hypothesis behind Insider Monkey's look at hedge-fund
ISTA rebuffs Valeant bid
Well, that was quick. Executives at ISTA Pharmaceuticals ( $ISTA ) have mulled over Valeant Pharmaceutical's ( $VRX ) $327 million unsolicited initial bid for the company, and found it lacking. (Valeant
